Novartis won regulatory approval last summer for a heart-failure pill, Entresto, that it called “one of the most remarkable drugs in cardiovascular medicine in the last several decades.” Since then, it has faced a problem: getting doctors to prescribe it.
from WSJ.com: US Business http://ift.tt/1Z1vxih
via IFTTT
No comments:
Post a Comment